SAM
FATE icon

Smartleaf Asset Management’s Fate Therapeutics FATE Stock Holding History

Smartleaf Asset Management’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$85 Hold
35
– – ﹤0.01% 3374
2026
Q1 		$40 Hold
35
– – ﹤0.01% 3448
2025
Q4 		$34 Hold
35
– – ﹤0.01% 3450
2025
Q3 		$35 Hold
35
– – ﹤0.01% 2987
2025
Q2 		$36 Hold
35
– – ﹤0.01% 2706
2025
Q1 		$29 Buy
+35
New +$43 ﹤0.01% 2854
2024
Q4 		– Sell
-389
Closed -$1.39K – 2953
2024
Q3 		$1.39K Buy
+389
New +$1.51K ﹤0.01% 2581

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Smartleaf Asset Management's FATE Position: Q2 2026 in Review

Smartleaf Asset Management held its Fate Therapeutics (FATE) position steady in Q2 2026 at 35 shares worth $85. The position accounts for ﹤0.01% of the portfolio, ranked #3374.

Smartleaf Asset Management first reported a position in FATE in Q3 2024 and has held it in 7 quarters since. The position peaked at $1.39K in Q3 2024. 156 funds tracked by Wall St. Rank hold FATE as of Q2 2026.

  • Smartleaf Asset Management held 35 shares of Fate Therapeutics worth $85 as of Q2 2026.
  • Smartleaf Asset Management left its Fate Therapeutics share count unchanged in Q2 2026.
  • Fate Therapeutics made up ﹤0.01% of Smartleaf Asset Management's portfolio in Q2 2026, its #3374 holding.
  • Smartleaf Asset Management first reported a position in Fate Therapeutics in Q3 2024 and has held it in 7 quarters since.
  • Smartleaf Asset Management's Fate Therapeutics position peaked at $1.39K in Q3 2024.
  • 156 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2026.

Based on Smartleaf Asset Management's 13F filing for Q2 2026, filed 12 Aug 2026.